WASHINGTON: US health authorities approved on Tuesday, after having denied twice, marketing a treatment against disorders of sexual desire in women, with a warning about the potentially harmful effects this drug. The Food and Drug Administration (FDA) also points out that this treatment, flibanserin, which will be marketed under the brand Addyi by the laboratory...
